Primary Gastric Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major primary gastric lymphoma markets reached a value of US$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.1 Billion by 2034, exhibiting a growth rate (CAGR) of 14.03% during 2024-2034.
The primary gastric lymphoma market has been comprehensively analyzed in IMARC's new report titled "Primary Gastric Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary gastric lymphoma (PGL) is a rare type of non-Hodgkin lymphoma that originates in the stomach's lymphatic tissue. The symptoms of this ailment can be vague and may mimic those of other gastrointestinal disorders, making diagnosis challenging. Individuals suffering from the illness might experience abdominal discomfort, pain, bloating, early satiety, unexplained weight loss, nausea, vomiting, etc. Due to its nonspecific presentation, timely recognition of PGL is crucial. The diagnosis of lymphoma involves a combination of methods. Endoscopy with biopsy is a pivotal step, allowing for the collection of tissue samples for microscopic examination. This investigation aids in identifying lymphoma cells and determining their specific subtype. Physicians might also recommend imaging studies, such as CT scans or MRIs, to assess the extent of the disease and exclude the involvement of various other organs. Numerous diagnostic tests, like blood work, including complete blood counts and molecular analysis, can also be utilized in patients.
The escalating incidences of gene mutations, leading to abnormal growth of lymphatic cells within the stomach lining, are primarily driving the primary gastric lymphoma market. In addition to this, the inflating utilization of effective treatments, such as chemotherapy regimens, radiotherapy, immunotherapy, and surgery, aimed at managing the disease and preventing its progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, since they help in leveraging drugs that specifically pinpoint certain molecules involved in the proliferation and survival of lymphoma cells, is further bolstering the market growth. Apart from this, the rising usage of endoscopic procedures, which enable minimally invasive diagnosis and treatment by directly visualizing and accessing the affected area, is acting as another significant growth-inducing factor. These techniques facilitate accurate staging of the ailment as well as offer a platform for biopsy and subsequent therapeutic interventions. Additionally, the growing awareness of complementary approaches like nutritional support and integrative therapies that can enhance the overall well-being of patients who are undergoing treatment is also augmenting the market growth. Furthermore, the emergent application of personalized medicine strategies, which hold the potential to optimize treatment outcomes and minimize adverse effects, is expected to drive the primary gastric lymphoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the primary gastric lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary gastric lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary gastric lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary gastric lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary gastric lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary gastric lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the primary gastric lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the primary gastric lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the primary gastric lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of primary gastric lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary gastric lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary gastric lymphoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with primary gastric lymphoma across the seven major markets?
What is the size of the primary gastric lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of primary gastric lymphoma?
What will be the growth rate of patients across the seven major markets?
Primary Gastric Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for primary gastric lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary gastric lymphoma market?
What are the key regulatory events related to the primary gastric lymphoma market?
What is the structure of clinical trial landscape by status related to the primary gastric lymphoma market?
What is the structure of clinical trial landscape by phase related to the primary gastric lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the primary gastric lymphoma market?
The primary gastric lymphoma market has been comprehensively analyzed in IMARC's new report titled "Primary Gastric Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary gastric lymphoma (PGL) is a rare type of non-Hodgkin lymphoma that originates in the stomach's lymphatic tissue. The symptoms of this ailment can be vague and may mimic those of other gastrointestinal disorders, making diagnosis challenging. Individuals suffering from the illness might experience abdominal discomfort, pain, bloating, early satiety, unexplained weight loss, nausea, vomiting, etc. Due to its nonspecific presentation, timely recognition of PGL is crucial. The diagnosis of lymphoma involves a combination of methods. Endoscopy with biopsy is a pivotal step, allowing for the collection of tissue samples for microscopic examination. This investigation aids in identifying lymphoma cells and determining their specific subtype. Physicians might also recommend imaging studies, such as CT scans or MRIs, to assess the extent of the disease and exclude the involvement of various other organs. Numerous diagnostic tests, like blood work, including complete blood counts and molecular analysis, can also be utilized in patients.
The escalating incidences of gene mutations, leading to abnormal growth of lymphatic cells within the stomach lining, are primarily driving the primary gastric lymphoma market. In addition to this, the inflating utilization of effective treatments, such as chemotherapy regimens, radiotherapy, immunotherapy, and surgery, aimed at managing the disease and preventing its progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, since they help in leveraging drugs that specifically pinpoint certain molecules involved in the proliferation and survival of lymphoma cells, is further bolstering the market growth. Apart from this, the rising usage of endoscopic procedures, which enable minimally invasive diagnosis and treatment by directly visualizing and accessing the affected area, is acting as another significant growth-inducing factor. These techniques facilitate accurate staging of the ailment as well as offer a platform for biopsy and subsequent therapeutic interventions. Additionally, the growing awareness of complementary approaches like nutritional support and integrative therapies that can enhance the overall well-being of patients who are undergoing treatment is also augmenting the market growth. Furthermore, the emergent application of personalized medicine strategies, which hold the potential to optimize treatment outcomes and minimize adverse effects, is expected to drive the primary gastric lymphoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the primary gastric lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary gastric lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary gastric lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary gastric lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary gastric lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary gastric lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the primary gastric lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the primary gastric lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the primary gastric lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of primary gastric lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary gastric lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary gastric lymphoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with primary gastric lymphoma across the seven major markets?
What is the size of the primary gastric lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of primary gastric lymphoma?
What will be the growth rate of patients across the seven major markets?
Primary Gastric Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for primary gastric lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary gastric lymphoma market?
What are the key regulatory events related to the primary gastric lymphoma market?
What is the structure of clinical trial landscape by status related to the primary gastric lymphoma market?
What is the structure of clinical trial landscape by phase related to the primary gastric lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the primary gastric lymphoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRIMARY GASTRIC LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRIMARY GASTRIC LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRIMARY GASTRIC LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PRIMARY GASTRIC LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRIMARY GASTRIC LYMPHOMA - UNMET NEEDS
10 PRIMARY GASTRIC LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 PRIMARY GASTRIC LYMPHOMA - MARKETED PRODUCTS
11.1 List of Primary Gastric Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PRIMARY GASTRIC LYMPHOMA - PIPELINE DRUGS
12.1 List of Primary Gastric Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. PRIMARY GASTRIC LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRIMARY GASTRIC LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRIMARY GASTRIC LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Primary Gastric Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Primary Gastric Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Primary Gastric Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Primary Gastric Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Primary Gastric Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Primary Gastric Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Primary Gastric Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Primary Gastric Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Primary Gastric Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Primary Gastric Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Primary Gastric Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Primary Gastric Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Primary Gastric Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Primary Gastric Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Primary Gastric Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Primary Gastric Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
16 PRIMARY GASTRIC LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRIMARY GASTRIC LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRIMARY GASTRIC LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRIMARY GASTRIC LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PRIMARY GASTRIC LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRIMARY GASTRIC LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PRIMARY GASTRIC LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRIMARY GASTRIC LYMPHOMA - UNMET NEEDS
10 PRIMARY GASTRIC LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 PRIMARY GASTRIC LYMPHOMA - MARKETED PRODUCTS
11.1 List of Primary Gastric Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PRIMARY GASTRIC LYMPHOMA - PIPELINE DRUGS
12.1 List of Primary Gastric Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. PRIMARY GASTRIC LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRIMARY GASTRIC LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRIMARY GASTRIC LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Primary Gastric Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Primary Gastric Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Primary Gastric Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Primary Gastric Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Primary Gastric Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Primary Gastric Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Primary Gastric Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Primary Gastric Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Primary Gastric Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Primary Gastric Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Primary Gastric Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Primary Gastric Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Primary Gastric Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Primary Gastric Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Primary Gastric Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Primary Gastric Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Primary Gastric Lymphoma - Access and Reimbursement Overview
16 PRIMARY GASTRIC LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRIMARY GASTRIC LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRIMARY GASTRIC LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
